NCT01219699 - A Study of BYL719 in Adult Patients With Advanced Solid Malignancies, Whose Tumors Have an Alteration of the PIK3CA Gene | Biotech Hunter

Enrollment

221

Participants

Timeline

Start Date

October 5, 2010

Primary Completion Date

February 5, 2015

Study Completion Date

April 16, 2020

Conditions

Advanced Solid Tumors With an Alteration of the PIK3CA GeneEstrogen Receptor Positive Breast Cancer

Interventions

DRUG

BYL719

BYL719 is an oral α-specific phosphatidylinositol-3-kinase (PI3K) inhibitor.

DRUG

Fulvestrant

"In adult patients with advanced solid malignancies whose tumors have an alteration (mutation or amplification) of the PIK3CA gene.~Fulvestrant is an estrogen receptor antagonist, administered by monthly intramuscular injection"

Trial Locations (11)

37203

Sarah Cannon Research Institute Dept.ofSarahCannonCancerCtr(4), Nashville

37232

Vanderbilt Univeristy SC, Nashville

45147

Novartis Investigative Site, Essen

94143

UCSF Medical Center, San Francisco

97080

Novartis Investigative Site, Würzburg

02114

Massachusetts General Hospital, Boston

77030-4009

MD Anderson Cancer Center/University of Texas MD Anderson, Houston

1066 CX

Novartis Investigative Site, Amsterdam

08035

Novartis Investigative Site, Barcelona

08907

Novartis Investigative Site, L'Hospitalet de Llobregat

OX3 7LJ

Novartis Investigative Site, Oxford